-EARNINGS RELEASE-

ELRON ELECTRONIC INDUSTRIES REPORTS \$2.6 MILLION NET INCOME IN THE FIRST OUARTER OF 2007

Tel Aviv, Israel, May 21, 2007 - Elron Electronic Industries Ltd. (NASDAQ &TASE: ELRN) today reported a net income of \$2.6 million, or \$0.09 per share, for the first quarter of 2007, compared to a net loss of \$3.5 million, or \$0.12 per share, in the first quarter of 2006.

Elron's net income in the first quarter of 2007 resulted mainly from a \$9.1 million gain (net of tax) from the merger between NetVision, Barak and GlobCall which was completed in January 2007. This gain was offset mainly by Elron's share in the net loss of its group companies in the amount of \$7.4 million.

Elron's net loss in the three months ended March 31, 2006 resulted mainly from its share in the net loss of its group companies in the amount of \$5.0 million and from the absence of gains from sales of shares of group companies or changes in holding in its group companies.

MAJOR INVESTMENTS AND EVENTS DURING THE FIRST QUARTER OF 2007 AND SUBSEQUENTLY

- *NetVision* completed the merger with Barak International Telecommunications Services and Globcall Communications on January 25, 2007, creating a company with over \$250 million in revenues. Elron now holds approximately 18% in NetVision.
- *ChipX* (a 29% holding), completed the acquisition of certain U.S. based business assets of Oki Semiconductor Company, which will potentially double ChipX's revenues in 2007.
- On March 15, 2007, Elron completed the acquisition of approximately 34% of the outstanding shares of *AqWise Wise Water Solutions Ltd.*, in consideration for approximately \$3.4 million. AqWise provides advanced biological wastewater treatment solutions which increase capacity and nutrient removal in wastewater treatment plants, utilizing advanced bio film technology.
- On April 19, 2007, Elron completed a new investment of approximately \$1.2 million in *BPT (Bio-Pure Technology) Ltd.* out of a \$2.5 million financing round for approximately 19% of BPT's outstanding shares. BPT provides advanced membrane-based separation solutions that address the unique needs of the water, wastewater treatment and various industries generating aggressive wastewater streams.
- On April 25, 2007, a definitive agreement for the sale by Elron's subsidiary, Elbit Ltd., of its real estate in Carmiel, Israel, was signed for approximately \$11.6 million. The sale is expected to be completed during the second quarter of 2007. Upon completion of the sale, Elron expects to record a gain, after tax of approximately \$3.5 million.
- Three of Elron's group companies, *BrainsGate Ltd.* (22% held), *Starling Advanced Communications Ltd.* (50% held directly and indirectly), and *SELA Semiconductor Engineering Laboratories Ltd.* (39% held directly and indirectly), are involved in an initial public offering process of their respective shares on the Tel-Aviv Stock Exchange. It is the intention of each of these companies to list on the TASE, subject to receiving a permit from the Israeli Securities Authority and market conditions. If these

proposed public offerings occur, Elron intends to participate by investing an aggregate amount of up to \$15 million. There is no assurance when or if at all, any of the proposed offerings will take place.

- Elron has purchased, in a series of open market transactions, approximately 391,000 ordinary shares of *Given Imaging Ltd.* ("Given Imaging") (Nasdaq & TASE: GIVN) for an aggregate purchase consideration of approximately \$9.9 million and its direct and indirect ownership interest in Given Imaging increased from approximately 20.8% to approximately 22.1% of Given Imaging's outstanding ordinary shares. In parallel transactions, Discount Investment Corporation Ltd. ("DIC"), a 49% shareholder of Elron, purchased the same number of shares of Given Imaging for the same aggregate consideration. It is the intention of each of Elron and DIC, subject to market conditions, to seek purchasing in parallel and on equal terms, of up to 2.5% of Given Imaging's outstanding shares, including the aforementioned purchases. There is no assurance that Elron and DIC will purchase the whole amount.
- On May 15, 2007 DIC, filed with the U.S. Securities and Exchange Commission, a preliminary statement on a Schedule TO-C regarding the possible purchase of additional shares of Elron, representing up to approximately 10% of Elron's outstanding shares, by way of a tender offer or in another manner. No timing, size or terms of such purchase have been determined and there is no assurance that such purchase will take place.

LIQUIDITY AND SHAREHOLDERS' EQUITY

As of March 31, 2007, Elron's cash, debentures and deposits amounted to approximately \$110.1 million compared with \$123.5 million at December 31, 2006. During the first quarter of 2007, Elron invested approximately \$6.6 million in new and existing group companies.

Shareholders' equity at March 31, 2007, was approximately \$301.1 million, representing approximately 94% of the total assets compared with \$297.5 million representing approximately 91% of total assets at December 31, 2006.

"We completed over the past six months three new investments in highly innovative water technology companies, making us an influential player in this emerging global market. In addition, we continue to build our group companies and to use our significant cash resources to invest in new companies as well as in our group companies", said Doron Birger, Elron's President and CEO.

Investors may access Elron's first quarter financial report and a detailed management report on the company's web site: www.elron.com

Conference call details:

Monday, May 21, 2007 10:00 a.m. (EDT); 5:00 p.m. Israel Dial in numbers:

In the US: 1 888 642 5032

In the UK: 0 800 051 8913

In Israel: 03 918 0691

International Participants: +972 3 918 0691

For your convenience, a **replay of the call** will be available starting two hours after the call ends until Wednesday, May 23, 2007. To access the replay please dial **1-888-782-4291** (US), +972-3-925-5927 (Israel) and 0-800-028-6837 (UK).

Elron Electronic Industries Ltd. (TASE & NASDAQ: ELRN), a member of the IDB Holding group, is a leading Israel-based technology holding company directly involved in the long-term performance of its group companies. Elron identifies potential technologies, creates strategic partnerships, secures financing, and recruits highly qualified management teams. Elron's group companies currently comprise a diverse range of publicly-traded and privately held companies primarily in the fields of medical devices, information & communications technology, clean technology and semiconductors. For further information, please visit www.elron.com

Company Contact:

Rinat Remler, Vice President & CFO Elron Electronic Industries Ltd. Tel. 972-3-6075555 elron@elron.net

(Any statements in this press release that may be considered forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. Actual results may differ from such forward-looking statements due to the risk factors discussed in periodic reports filed by the Company with the Securities and Exchange Commission, which the Company urges investors to consider).

Tables to follow

CONDENSED CONSOLIDATED BALANCE SHEETS

In thousands of U.S. Dollars

In thousands of C.S. Donars	March 31, 2007 Unaudited	December 31, 2006 Audited
ASSETS Total current assets	\$ 124,391	\$ 134,033
INVESTMENTS AND LONG-TERM RECEIVABLES Investments in affiliated companies Investments in other companies and long-term receivables Deferred taxes Severance pay deposits	112,481 69,009 7,475 1,712	100,392 68,215 9,182 1,662
Total long-term assets	190,677	179,451
PROPERTY AND EQUIPMENT, NET	1,269	7,223
INTANGIBLE ASSETS	5,538	5,542
Total assets	\$ 321,875	\$ 326,249
LIABILITIES AND SHAREHOLDERS' EQUITY Total current liabilities	\$ 13,674	\$ 20,535
LONG-TERM LIABILITIES Long-term loans from banks and others Accrued severance pay and retirement obligations Deferred taxes	2,147 2,405 1,365	2,113 2,209 1,408
Total long-term liabilities	5,917	5,730
MINORITY INTEREST	1,137	2,480
Total Shareholders' Equity	301,147	297,504
Total liabilities and shareholdes' equity	\$ 321,875	\$ 326,249

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

In thousands of U.S. Dollars, except share and per share data

in thousands of O.S. Donars, except share and per share d	Three months ended March 31, 2007 2006		Year ended December 31, 2006	
	Unai	udited	Audited	
INCOME Revenues	\$ 981	\$ 3,322	\$ 12,863	
Equity in losses of affiliated companies Gain from disposal of businesses and affiliated companies and changes in holdings in affiliated	(5,308)	(3,495)	(17,740)	
companies, net	11,714	16	2,547	
Other income, net	473	2,629	29,310	
Financial income, net	1,406	1,084	4,051	
	9,266	3,556	31,031	
COSTS AND EXPENSES	6,811	8,514	36,113	
Income (loss) before taxes on income Taxes on income Income (loss) after taxes on income	2,455 (1,522) 933	(4,958) (282) (5,240)	5,082 (1,110) 6,192	
Minority interest in losses (income) of subsidiaries	1,635	1,727	9,224	
Net income (loss)	\$ 2,568	\$ (3,513)	\$ 3,032	
Income (loss) per share: Basic: Net income (loss)	\$ 0.09	\$ (0.12)	\$ 0.10	
Diluted:				
Net income (loss)	\$ 0.09	\$ (0.12)	\$ 0.07	
Weighted average number of ordinary shares used in computing basic net income (loss) per share (thousands)	29,601	29,514	29,532	
Weighted average number of ordinary shares used in computing diluted net income (loss) per share (thousands)	29,696	29,514	29,624	

MANAGEMENT REPORT FOR THE FIRST QUARTER ENDED MARCH 31, 2007

The following discussion should be read in conjunction with our Condensed Interim Consolidated Financial Statements as of March 31, 2007 and notes thereto and with our Annual Consolidated Financial Statements as of December 31, 2006 and notes thereto. This report contains forward-looking statements that involve risks and uncertainties. Such forward-looking statements may be identified by the words "anticipate", "believe", "estimate", "expect", "plan" and similar expressions. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of certain factors, including, but not limited to, those discussed in our filings with the Securities and Exchange Commission from time to time.

OVERVIEW

We are a high technology operational holding company that operates through subsidiaries and affiliated companies, referred to as our group companies. Founded in 1962, we have been a major force in the development of the Israeli high technology industry by building Israeli and Israel-related companies with technologies in the fields of medical imaging, advanced defense electronics, telecommunications, semiconductors and software products and services. Elron's group companies currently comprise of a group of publicly-traded and privately held companies primarily in the fields of medical devices, information & communications technology, clean technology and semiconductors.

Our activities range from operational control over the business to involvement in the management of our group companies in which we maintain controlling or significant holdings, and, in a limited number of cases, non-significant holdings. We participate in the management of most of our group companies by means of active membership on their boards of directors and board committees. As a result, we are involved in matters of policy, strategic planning, marketing, selecting and manning senior management positions, approving investments and budgets, financing and the overall ongoing monitoring of our group companies' performance. In addition to our representation on the boards of directors of our group companies, we provide hands-on assistance to the group companies' management in support of their growth. We view our hands-on involvement in the operations of our group companies as a key element of our business. Our group companies therefore benefit from the experience of our management team in various areas in which they need support and leadership, including, but not limited to, strategic planning, research and development guidance, identifying joint venture opportunities, introductions to potential customers and investors, risk management, market analysis, business plan preparation, budgetary control, and legal support.

Technology industries are characterized by the high degree of risk inherent in their products, their continuous technological innovation and their penetration into world markets, which requires investment of considerable resources and continuous development efforts. The future success of our group companies is dependent upon their technological quality, prices and nature of their products in comparison to their competitors and their ability to introduce new products to the markets at the right time, while offering cost effective solutions suitable to their customers' needs as well as their ability to raise financing and the condition of the capital markets.

We expect to continue to build and realize value for our shareholders through the sale to third parties of a portion or all of our holdings in, or the issuance of shares by, our group companies, while simultaneously pursuing the acquisition of, or investment in, new and existing companies at different stages of development including early stage and more mature companies. We believe that this strategy provides the ability to increase shareholder value as well as to create capital to support the growth of our group companies and to invest in new opportunities. The nature of our business, therefore, will result in volatility in our results of operations, depending on the transactions that occur within a particular period.

Our net income (or loss) in any given period is due, for the most part, to the results of operations of those of our group companies which are accounted by us under the consolidation or equity method of accounting and dispositions and changes in our holdings of group companies. As most of our group companies are technology companies which have not yet generated significant revenues and which invest considerable resources in research and development and in marketing activities, we have experienced, and expect to continue to experience, losses in respect of these companies to the extent they are accounted by us under the consolidation or equity method of accounting.

Our capital resources in any given period are primarily affected by the extent of our investment in existing and new companies and the realization of certain holdings as well as the impact of any dividends or distributions to our shareholders. The results of operations of our group companies, and consequently, our results of operations and capital resources, are affected by general economic conditions as well as by factors specifically related to the technology markets, which also affect the ability of our group companies to raise financing and our ability to dispose of holdings and realize gains from our holdings.

TREND INFORMATION

Technology industries are affected by economic trends and the condition of the capital markets. Since the second half of 2003, there has been a recovery in the technology sectors and capital markets from the downturn which commenced in 2001. This trend was reflected in the improvement in the results of operations of most of our group companies as well as the raising of funds from new strategic and other investors in private placements completed by some of our group companies. In addition, we recorded

significant gains from realizing certain of our holdings, mainly in 2004 as a result of the sale of our holdings in Elbit Systems Ltd. (Nasdaq: ESLT) ("Elbit Systems"), and from the sale of our shares in Partner Communications Company Ltd. (Nasdaq: PTNR) ("Partner") in 2005 and 2006. Total proceeds from exit transactions since 2004 amounted to approximately \$375 million. We have used the proceeds to distribute a dividend, in 2005, of \$88.5 million to our shareholders and to continue investing in existing and new group companies. Since 2004 we and our subsidiary, RDC Rafael Development Corporation Ltd. ("RDC"), invested approximately \$187 million of which approximately \$84 million was in 13 new companies and the balance of approximately \$98 million was in existing group companies (mainly in Given Imaging). Should the improvement in the technology sectors and capital markets continue, we anticipate that it will have a positive effect on our group companies and their ability to raise additional capital. However, there is no assurance that a downturn will not re-occur or that the technology sector will continue to grow.

MAJOR TRANSACTIONS AND INVESTMENTS DURING THE FIRST QUARTER AND SUBSEQUENTLY

NetVision Ltd. ("NetVision"). On January 25, 2007, NetVision, then held 36% by Elron and 36% by Discount Investment Corporation Ltd. ("DIC"), a 49% shareholder of Elron, completed a merger with Barak I.T.C (1998) International Telecommunications Services Corp Ltd. ("Barak") and a merger between NetVision and GlobCall Communications Ltd. ("Globcall"). Barak is a subsidiary of Clal Industries and Investments Ltd. ("Clal"). Elron, Clal and DIC, are all part of the IDB group. Following the transactions, Elron's, DIC's and Clal's holdings in NetVision are approximately 18%, 25% and 29%, respectively. As a result of the Barak merger and GlobCall merger, we recorded a gain of \$10.3 million (\$9.1 million net of tax). Elron continues to account for NetVision under the equity method due to a shareholders agreement between DIC, Elron and Clal in connection with voting at shareholders meetings including the appointment of directors.

ChipX Inc. ("ChipX"). ChipX Corporation, a provider of differentiated ASIC (application specific integrated circuits) solutions, in which we hold 29%, completed in February 2007 the acquisition of the US ASIC business assets of Oki Semiconductor Company, a division of Oki America Inc. Oki is a global semiconductor company headquartered in Japan with offices worldwide offering a full range of digital integrated circuits from real time controllers to micro processors and network devices focusing on the communications and security industries. In addition, ChipX and Oki Semiconductor have signed a collaboration agreement which will enable ChipX to gain access to Oki Semiconductor's technology, libraries and foundry services. This transaction will boost ChipX's ASIC team capabilities and enable it to offer its customers a range of differentiated ASIC solutions of embedded arrays, gate arrays, structured ASICs and standard cell ASICs. In April, 2007 ChipX completed a private placement of \$4.0 million from existing shareholders, of which we invested \$1.3 million. The proceeds will be used mainly to finance ChipX sales and marketing activities in connection to the acquisition of the US ASIC business of Oki Semiconductors.

New Investment in AqWise – Wise Water Solutions Ltd. ("AqWise"). On March 15, 2007 we completed the acquisition of approximately 34% of the outstanding shares of AqWise, an Israeli-based water technology company, from certain existing shareholders of AqWise in consideration for approximately \$3.4 million. AqWise provides advanced biological wastewater treatment technologies which increase capacity and nutrient removal in wastewater treatment plants, utilizing advanced bio film technology. AqWise's solutions have been implemented worldwide in over 20 municipal and industrial plants, in various fields: pulp and paper, food and beverage, agricultural wastewater, chemical plants and aquaculture farms.

New Investment in BPT (Bio-Pure Technology) Ltd. ("BPT"). On April 19, 2007, Elron completed a new investment of approximately \$1.1 million in BPT out of a \$2.5 million financing round which was led by Elron and Aurum Ventures M.K.I. Following the investment, Elron holds approximately 19% of BPT's outstanding shares. BPT, an Israeli based water technology company, provides advanced membrane-based separation solutions that address the unique needs of the water, wastewater treatment and chemical process industries; and enables high-grade separation and re-use of water and valuable materials within the process. BPT offers a cost-effective and environment-friendly process, employing its proprietary HMTTM (Hybrid Membrane Treatment) solution, based on NF (Nano-Filtration) membranes exhibiting high stability, selectivity and reliability. BPT's solutions address aggressive wastewater streams and water-intensive applications in a wide range of industries, such as pharmaceuticals, chemicals, agrochemicals, metals, food & beverage, drinking water, water re-use and desalination.

Sale of Real Estate. On April 25, 2007, a definitive agreement for the sale by our subsidiary, Elbit Ltd., of its real estate in Carmiel, Israel, was signed for approximately \$11.6 million. The agreement is subject to the right of the current tenant of the property, to notify Elbit within a period of thirty days, if it wishes to purchase the property on the same terms. The sale is expected to be completed during the second quarter of 2007. Upon completion of the sale, Elron expects to record a gain, after tax of approximately \$3.5 million.

Proposed Initial Public Offerings By Three Of Our Group Companies On The Tel Aviv Stock Exchange ("TASE"). On April 29, 2007 we announced that three of our group companies, BrainsGate Ltd., in which we hold approximately 22%, Starling Advanced Communications Ltd. ("Starling"), in which we hold approximately 27% directly and approximately 46% indirectly through our subsidiary RDC, and SELA – Semiconductor Engineering Laboratories Ltd. ("Sela"), in which we hold approximately 12% directly and approximately 54% indirectly through RDC, have filed requests with the Israeli Securities Authority and the TASE for proposed public offerings of their respective shares on the TASE. It is the intention of each of these companies to list on the TASE during the second quarter of 2007 or as soon as possible thereafter, subject to receiving a permit from the Israeli Securities Authority and market conditions. The pricing and extent of each proposed offering has not yet been determined. We

intend to participate in these public offerings, by investing an aggregate amount of up to \$15 million. There is no assurance when or if at all, any of the proposed offerings will take place.

Purchase of Given Imaging Ltd. ("Given Imaging") Shares. During May 2007 and through May 17, 2007 we purchased approximately391,000 shares of Given Imaging on the open market for an aggregate purchase price of approximately \$9.9 million. As a result, our direct and indirect (through our subsidiary RDC – Rafael Development Corporation ("RDC")) interest in Given Imaging increased from approximately 20.8% to approximately 22.1% of the outstanding shares of Given Imaging. DIC simultaneously purchased the same number of shares of Given Imaging for the same aggregate purchase price and is now owns 15.3% of the outstanding shares of Given Imaging. It is the intention of each of Elron and DIC, subject to market conditions, to seek purchasing in parallel and on equal terms, up to 2.5% of Given Imaging's outstanding shares, including the aforementioned purchases. There is no assurance that Elron and DIC will purchase the whole amount.

DIC preliminary statement to purchase up to approximately 10% of Elron's outstanding shares. On May 15, 2007 DIC, filed with the U.S. Securities and Exchange Commission, a preliminary statement on a Schedule TO-C in connection with a prospectus filed by DIC on May 15, 2007 (in Hebrew) with the Israeli Securities Authority and the Tel Aviv Stock Exchange (the "Prospectus"). In the Prospectus, DIC stated that it is considering purchasing additional shares of Elron, representing up to approximately 10% of Elron's outstanding shares, by way of a tender offer or in another manner. No timing, size or terms of such purchase have been determined and there is no assurance that such purchase will take place.

CERTAIN U.S. FEDERAL INCOME TAX CONSIDERATIONS

See our management report for the year ended December 31, 2006, regarding Elron's status with respect to the U.S. tax provisions regarding passive foreign investment companies ("PFIC").

CRITICAL ACCOUNTING POLICIES

We prepare our consolidated financial statements in conformity with accounting principles generally accepted in the United States ("US GAAP"). Our significant accounting policies are more fully described in Note 2 of the Notes to our 2006 Annual Consolidated Financial Statements. The accounting policies which are particularly important to the assessment of our financial position and results of operations are described in the management report for the year ended December 31, 2006.

In the first quarter of 2007 we adopted FASB Interpretation No. 48, "Accounting for Uncertainty in Income Taxes, an Interpretation of FASB Statement No. 109" ("FIN 48"). For more information regarding FIN 48, see our Condensed Interim Consolidated Financial Statements as of March 31, 2007. The adoption of FIN 48 as of January 1, 2007 did not have any effect on the Company's retained earnings and financial position.

BASIS OF PRESENTATION

Consolidation. Our consolidated financial statements include the accounts of Elron and all of our direct or indirect (through Elbit and DEP) controlled subsidiaries. The following are our main subsidiaries:

Three months ended March 31

2007	20	006
RDC	RDC	$3DV^1$
SELA	Galil Medical ¹	Starling
Medingo	SELA	Enure ²
Starling	Medingo	

¹ Galil Medical and 3DV have been consolidated through December 2006.

Equity Method. Our main group companies held by us or through Elbit, DEP and/or RDC accounted for under the equity method of accounting include:

	2007	,	2006
Given Imaging	$3DV^1$	Given Imaging	AMT
NetVision	AMT	Oncura ²	Notal Vision
ChipX	Notal Vision	NetVision	CellAct ³
Wavion	AqWise ⁴	ChipX	
Galil Medical ¹	-	Wavion	

¹ Galil Medical and 3DV have been accounted based on the equity method since December 2006

Other investments. Our main group companies held by us which are accounted for under the cost method or as available-for- sale include:

² Enure has been consolidated through August 2006.

² Oncura was sold in December 2006

³CellAct was sold in February 2007

⁴ AqWise was purchased in March 2007

Three months ended March 31,

Three months ended martin etc.					
	2007 2006				
Jordan Valley	BrainsGate	Neurosonix	Jordan Valley	BrainsGate	
Impliant	NuLens	Atlantium	Impliant	NuLens	
Teledata	Safend	Enure ¹	Teledata		

¹ Enure has been accounted at cost from August 2006

Available-for-sale Securities - As of March 31, 2007 - Elbit Vision Systems and M-Wise.

RESULTS OF OPERATIONS

Three months ended March 31, 2007 compared to three months ended March 31, 2006.

The following tables set forth our results of operations in the reported period:

_	Three months ended March 31,		
	2007 2006 (millions of \$, except per share data)		
Net income (loss)	2.6	(3.5)	
Net income (loss) per share	0.09	(0.12)	

The net income we reported in the three months ended March 31, 2007 resulted mainly from a \$9.1 million gain (net of tax) from the merger between NetVision, Barak and GloabCall (see above under "MAJOR TRANSACTIONS AND INVESTMENTS DURING THE FIRST QUARTER OF 2007"). This gain was offset mainly by our share in the net loss of our group companies in the amount of \$7.4 million.

The net loss we reported in the three months ended March 31, 2006 resulted mainly from our share in the net loss of our group companies in the amount of \$5.0 million and from the absence of gains from sales of our share of group companies.

The following table summarizes our operating results:

	Three months ended March 31	
	2007	2006
	(millions	s of \$)
Net revenues	1.0	3.3
Net loss from equity investments	(5.3)	(3.5)
Gains from disposal of business and affiliated companies		
and changes in holdings in affiliated companies	11.7	-
Other income, net	0.5	2.7
Finance income, net	<u>1.4</u>	<u>1.1</u>
Total income	1.4 9.3 0.5	1.1 3.6 1.8
Cost of revenues	0.5	1.8
Operating expenses	6.3	6.7
Total costs and expenses	<u>6.8</u>	<u>8.5</u>
Loss from continuing operations before income taxes	6.8 2.5	(4.9)
Taxes on income	(1.5)	(0.3)
Minority interest	<u>1.6</u>	<u>1.7</u>
Net income (loss)	<u>2.6</u>	<u>(3.5)</u>

Income

Net revenues. Net revenues consisted of sales of products and services by our subsidiaries, mainly SELA (and in 2006 – also Galil Medical). The following table sets forth these revenues:

	Three months en	Three months ended March 31,	
	2007	2006	
	(millions	s of \$)	
Galil Medical ¹	-	1.8	
SELA	<u>1.0</u>	<u>1.5</u>	
	<u>1.0</u>	3.3	
Galil Medical has bee	n consolidated through Dec	cember 2006.	

Share in net losses of affiliated companies. Our share in net losses of affiliated companies resulted from our holdings in certain investments that are accounted for under the equity method (see above under "Basis of Presentation"). Our share in net losses of affiliated companies amounted to \$5.3 million in the three months ended March 31, 2007, compared to \$3.5 million in the same period in 2006. The increase resulted primarily from accounting for our investment in Galil Medical and 3DV in the three months ended March 31, 2007 based on the equity method while their results in the same period last year were consolidated.

Highlights of the Results of Operations of Our Major Affiliates:

Given Imaging (Nasdaq: GIVN) (a 20.8% holding directly and indirectly through RDC as of March 31, 2007). Given Imaging Ltd. ("Given Imaging"), a medical device company that develops, manufactures and markets innovative diagnostic systems for visualizing the gastrointestinal tract, using a disposable miniature swallowable video capsules, recorded revenues of \$23.1 million in the first quarter of 2007 compared to \$20.3 million in the first quarter of 2006. Given Imaging's net income in the first quarter of 2007 was \$0.1 million, compared to net loss of \$3.0 million in the first quarter of 2006. Excluding the effect of the adoption of FAS123R, Given Imaging reported non-GAAP net income of \$1.2 million in the first quarter of 2007, compared to a non- GAAP net loss of \$1.7 million in the same period of 2006.

In April, Japan's Ministry of Health, Labor and Wealth approved the PillCam SB Capsule and equipment for sale and marketing. In addition, Given Imaging signed a global strategic agreement with Fujinon Corporation to collaborate on research and development and sourcing as well as non-exclusive distribution activities.

Galil Medical (a 20.5% holding directly and indirectly through RDC). Galil Medical is a medical device company that develops, manufactures and markets medical supplies based on innovative cryotherapy technology while incorporating powerful freezing technology and revolutionary needle design to destroy malignant and benign tumors. Galil Medical revenues in the three month period ended March 31, 2007 amounted to \$6.6 million, compared to \$1.8 million in the same period in 2006. Through December 2006 Galil Medical's revenues derived mainly from the supply of cryo products and R&D services to Oncura, in which it held a 25% interest which Galil Medical sold in December 2006. At the same time Galil purchased from Oncura its urology related cryotherapy business, thereby resulting in an increase in Galil Medical's revenues. Galil Medical's operating loss in the three month period ended March 31, 2007 amounted to \$1.7 million, compared to \$0.1 million in the same period in 2006, resulting from higher level of research and development and sales and marketing activities as a result from the purchase of the cryotherapy business.

NetVision (a 18% holding) (TASE: NTSN). The following results of NetVision for the first quarter of 2007 and 2006 reflect the combined results of NetVision, Barak and GlobCall (hereafter: "NetVision Group") based on generally accepted accounting principles (GAAP) in Israel. NetVision Group's revenues in the three month period ended March 31, 2007 amounted to \$72.0 million, an increase by 3% from \$70.2 million in 2006. NetVision group's operating income in the three month period ended March 31, 2007 amounted to \$2.9 million, compared to \$6.2 million in the same period of 2006 and its net income amounted to \$2.1 million compared to net loss \$0.3 million, respectively. NetVision Group's broadband customer base at March 31, 2007 reached approximately 512,000 compared to 498,000 at December 31, 2006. NetVision's operating currency is the New Israeli Shekel (NIS) and accordingly, all figures above are translations for convenience purposes of NetVision's NIS figures into US dollars at the representative rate of exchange prevailing at March 31, 2007 according to which \$1.00 equaled NIS 4.155.

We expect that most of our group companies as well as new companies in which we will invest will continue to recognize losses in future periods, as they invest significant resources in research and development and sales and marketing activities and have not yet generated significant revenues. Our results of operations will therefore be affected by the extent of our share in their net losses (to the extent they are reported under the equity or consolidation method of accounting).

Gains from Disposal of Businesses and Affiliated Companies and Changes in Holdings in Affiliated Companies. Gains from disposal of businesses and affiliated companies and changes in our holdings in affiliated companies in the three months ended March 31, 2007 amounted to \$11.7 million, mainly as a result of a \$10.3 million gain (\$9.1 net of tax) from the merger between NetVision, Barak and Globcall, a \$1.0 million gain from exercise of options and debentures in Netvision and a \$0.5 million gain from the sale of our 45% interest in CellAct in consideration for \$0.8 million. No gains from disposal of businesses and affiliated companies and changes in our holdings in affiliated companies were reported in the three month period ended March 31, 2006.

Other Income, *net*. Other income, net, amounted to \$0.5 million in the three months ended March 31, 2007 compared to \$2.7 million in the same period in 2006. The gain in first quarter of 2007 was mainly due to the sale of some of Mwise shares held by us for \$0.5 million. The gain in first quarter of 2006 was mainly due to a \$2.7 million gain resulting from the settlement of Mediagate's bank loan.

Finance income, net. Finance income, net, amounted in the three months ended March 31, 2007 to \$1.4 million, compared to \$1.1 million in the same period in 2006, mainly as a result of higher interest rates on our deposits and debentures.

Expenses

Cost of revenues. Cost of revenues consisted primarily of expenses related to salaries and hardware associated with delivering products and services of our subsidiaries, mainly SELA (in 2006 – also Galil Medical). Cost of revenues in the three month period ended March 31, 2007 amounted to \$0.5 million, compared to \$1.8 million in the same period in 2006.

Operating expenses. Operating expenses are comprised of research and development expenses, sales and marketing and general and administrative expenses of our and RDC's corporate operations and of our subsidiaries, mainly SELA and Starling (and in 2006 also Galil Medical and 3DV). The following table sets forth the operating expenses:

Three months ended Ma	arch 31,
-----------------------	----------

Timee months ended march 31,	
2007	2006
(million	s of \$)
2.1	1.6
-	0.7
0.6	1.1
1.7	1.2
-	0.6
1.4	0.5
-	0.6
<u>0.5</u>	<u>0.3</u>
<u>6.3</u>	<u>6.7</u>
	2007 (million 2.1 - 0.6 1.7 - 1.4 - 0.5

¹ Galil Medical and 3DV have been consolidated through December 2006.

SELA's operating expenses amounted to \$0.6 million in the three months ended March 31, 2007, compared to \$1.1 million in the same period in 2006 and its operating loss amounted to \$0.1 million and \$0.2 million, respectively.

Starling's operating expenses and operating loss amounted to \$1.7 million in the three months ended March 31, 2007, compared to \$1.2 million in the same period in 2006. The increase resulted from the increase in research and development expenses.

LIQUIDITY AND CAPITAL RESOURCES

Consolidated cash, debentures and deposits at March 31, 2007, were approximately \$113.4 million compared with \$128.7 million at December 31, 2006. At March 31, 2007, corporate cash, debentures and deposits were \$110.1 million compared with \$123.5 million at December 31, 2006.

The main sources of corporate cash and other liquid instruments in the first quarter of 2007, were \$0.5 million and \$0.4 million of proceeds from the sale of Mwise and CellAct shares, respectively.

The main uses of the corporate cash and other liquid instruments in the first quarter of 2007, were \$6.6 million of investments in our group companies, which included \$3.4 million investment in AqWise, \$1.8 million investment in AMT, a \$0.8 million investment in Wavion, a \$0.4 million loan to Starling and a \$0.1 million loan to BPT. In addition, we paid during the first quarter tax liability in the amount of \$7.6 million, mainly with respect to the sale of Partner shares at the end of 2006.

Consolidated working capital at March 31, 2007 amounted to \$110.7 million compared to \$113.5 million at December 31, 2006.

Consolidated loans at March 31, 2007, were approximately \$6.8 million, compared to \$6.3 million at December 31, 2006.

Subsequent to March 31, 2007 and through May 16, 2007, we invested an additional aggregate amount of approximately \$13.3 million, which include mainly \$9.9 million purchase of Given Imaging shares in the open market, \$1.3 million in ChipX, \$0.8 million loan to Teledata and \$1.0 million in BPT. We intend to purchase additional shares of Given Imaging (see above under "MAJOR TRANSACTIONS AND INVESTMENTS DURING THE FIRST QUARTER OF 2007 AND SUSEQUENTLY").

Our investment policy for managing our funds is in general to invest in bank deposits and U.S. government securities with high liquidity.

We believe that our existing capital will be sufficient to fund our and our subsidiaries' operations and our investment plan in existing and new companies for at least the next twelve months.

Shareholders' equity at March 31, 2007, was approximately \$301.1 million, representing approximately 94% of the total assets compared with \$297.5 million representing approximately 91% of total assets at December 31, 2006.

² Enure has been consolidated through August 2006.

CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

As of March 31, 2007 (Unaudited)

CONDENSED INTERIM CONSOLIDATED

FINANCIAL STATEMENTS

AS OF MARCH 31, 2007

UNAUDITED

INDEX

	Page
Consolidated Balance Sheets	1-2
Consolidated Statements of Operations	3
Statements of Changes in Shareholders' Equity	4
Consolidated Statements of Cash Flows	5-6
Notes to the Consolidated Financial Statements	7-13
Annex to the Consolidated Financial Statements	14

CONSOLIDATED BALANCE SHEETS

U.S. dollars in thousands, except share and per share data

	March 31, 2007 Unaudited			ecember 31, 2006
ASSETS CURRENT ASSETS				
Cash and cash equivalents	\$	30,475	\$	52,954
Short-term investments	Ψ	17,533	Ψ	19,917
Available for sale marketable securities		65,352		55,862
Trade receivables		619		642
Other receivables and prepaid expenses*		3,092		3,043
Inventories		1,509		1,615
Asset held for sale		5,811		-
Total current assets		124,391		134,033
INVESTMENTS AND LONG-TERM RECEIVABLES				
Investments in affiliated companies		112,481		100,392
Investments in other companies and long-term receivables*		69,009		68,215
Deferred taxes		7,475		9,182
Severance pay deposits		1,712		1,662
Total investments and long-term receivables		190,677		179,451
PROPERTY AND EQUIPMENT, NET		1,269		7,223
INTANGIBLE ASSETS				
Goodwill		2,742		2,742
Other intangible assets		2,796		2,800
Total intangible assets		5,538		5,542
Total assets	\$	321,875	\$	326,249

^{*} Includes short-term receivables from related parties in the aggregate amount of \$154 and \$95 as of March 31, 2007 and December 31, 2006, respectively, and long-term receivables from related parties in the aggregate amount of \$475 and \$467 as of March 31, 2006 and December 31, 2006, respectively.

CONSOLIDATED BALANCE SHEETS U.S. dollars in thousands, except share ar

U.S. dollars in thousands, except share and per share data		
	larch 31, 2007 naudited	 ecember 31, 2006
LIABILITIES AND SHAREHOLDERS' EQUITY CURRENT LIABILITIES Short-term loans from banks and others Current maturities of long-term loans from banks and others Trade payables Other payables and accrued expenses	\$ 2,353 2,287 2,154 6,880	\$ 1,891 2,249 2,988 13,407
Total current liabilities	 13,674	 20,535
LONG-TERM LIABILITIES Long-term loans from banks and others Accrued severance pay and retirement obligations Deferred taxes	2,147 2,405 1,365	 2,113 2,209 1,408
Total long-term liabilities	 5,917	 5,730
MINORITY INTEREST	1,137	 2,480
SHAREHOLDERS' EQUITY: Ordinary shares of NIS 0.003 par value; Authorized - 35,000,000 shares as of March 31, 2007 and December 31, 2006; Issued and outstanding: 29,600,775 and 29,592,748 shares as of March 31, 2007 and December 31, 2006, respectively. Additional paid-in capital Accumulated other comprehensive income Retained earnings	9,573 273,056 2,247 16,271	 9,573 272,930 1,298 13,703
Total shareholders' equity	 301,147	 297,504
Total liabilities and shareholders' equity	\$ 321,875	\$ 326,249

CONSOLIDATED STATEMENTS OF OPERATIONS

U.S. dollars in thousands, except share and per share data

, .		Three ended M		ear ended cember 31,		
		2007		2006		2006
		Una	udite	ed		
INCOME						
Revenues*	\$	981	\$	3,322	\$	12,863
Equity in losses of affiliated companies	_	(5,308)		(3,495)	7	(17,740)
Gain from disposal of businesses and affiliated companies and		(- ,)		(-,,		(',' ','
changes in holdings in affiliated companies, net		11,714		16		2,547
Other income, net		473		2,629		29,310
Financial income, net		1,406		1,084		4,051
		9,266		3,556		31,031
COSTS AND EXPENSES		,,200				31,031
Cost of revenues		462		1,845		6,625
Research and development costs, net		2,375		2,908		11,758
Marketing and selling expenses, net		516		875		4,717
General and administrative expenses		3,454		2,881		12,995
Amortization of intangible assets		4		5		18
		6,811		8,514		36,113
Income (loss) before taxes on income		2,455		(4,958)		(5,082)
Taxes on income		(1,522)		(282)		(1,110)
Income (loss) after taxes on income		933		(5,240)		(6,192)
Minority interest in losses of subsidiaries		1,635		1,727		9,224
Net income (loss)	\$	2,568	\$	(3,513)	\$	3,032
Net meonic (1088)	Ψ	2,300	Ψ	(3,313)	Ψ	3,032
Income (loss) per share: Basic:						
Net income (loss)	\$	0.09	\$	(0.12)	\$	0.10
, ,						
Diluted:	Φ.	0.00	Φ.	(0.10)	Φ.	0.05
Net income (loss)	\$	0.09	\$	(0.12)	\$	0.07
Weighted average number of ordinary shares used in computing						
basic net income (loss) per share (thousands)		29,601		29,514		29,532
•			_			
Weighted average number of ordinary shares used in computing diluted net income (loss) per share (thousands)		29,696		29,514		29,624
unuted het income (loss) per share (mousands)		29,090		29,314		29,024

^{*} Includes revenues from related parties in the amount of \$1,744 for the three months ended March 31, 2006 and \$6,699 for the year ended December 31, 2006, respectively.

STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY

U.S. dollars in thousands, except share and per share data

	Number of shares	Sha	are capital		Additional id-in capital		occumulated other mprehensive income		Retained earnings	S	Total hareholders' equity		Total nprehensive come (loss)
Audited							_						
Balance as of January 1, 2006	29,483,455	\$	9,572	\$	271,132	\$	10,741	\$	10,671	\$	302,116		
Exercise of options Stock - based compensation	109,293		1		527 344						528 344		
Capital transaction in affiliated company (gain on purchase by	-		-		344		-		-		344		
affiliate of its subsidiary's preferred stock)	_		_		927		_		_		927		
Other comprehensive loss, net of tax:					,_,						721		
Unrealized gain on available for sale securities	-		-		-		6,493		-		6,493		
Reclassification adjustment for gain realized included in net													
income	-		-		-		(16,645)		-		(16,645)		(16,653)
Foreign currency translation adjustments	-		-		-		709		2.022		709		709
Net income									3,032		3,032		3,032
Balance as of December 31, 2006	29,592,748	\$	9,573	\$	272,930	\$	1,298	\$	13,703		297,504		
Total comprehensive loss												\$	(12,912)
Exercise of options	8,027		-		40		-		-		40		
Stock - based compensation Other comprehensive loss, net of tax:	-		-		86		-		-		86		
Unrealized gain on available for sale securities	_						1,204				1,204		
Reclassification adjustment for gain realized included in net loss			-		_		(487)		_		(487)		(487)
Foreign currency translation adjustments included in net income							(.07)				(.07)		(.07)
due to decrease in holdings in affiliated company							(265)				(265)		(265)
Foreign currency translation adjustments	-		-		-		497		-		497		497
Net income			-						2,568		2,568		2,568
Balance as of March 31, 2007 Unaudited	29,600,775	\$	9,573	\$	273,056	\$	2,247	\$	16,271	\$	301,147		
Total comprehensive income				_	-			_	•		•	\$	2,313
													,
Balance as of January 1, 2006	29,483,455	\$	9,572	\$	271,132	\$	10,741	\$	10,671	\$	302,116		
Exercise of options	48,500		-		242						242		
Stock - based compensation	-		-		94		-		-		94		
Other comprehensive loss, net of tax:													
Unrealized loss on available for sale securities	-		-		-		(1,480)		-		(1,480)	\$	(1,480)
Reclassification adjustment for loss realized and other than temporary impairment included in net loss							242				242		242
Foreign currency translation adjustments	_		_		_		(75)		-		(75)		(75)
Net loss	_		_		_		(73)		(3,513)		(3,513)		(3,513)
	20.521.055	Φ.	0.572	Φ.	071 460	Φ.	0.426	Φ.	* * * * * * * * * * * * * * * * * * * *	Φ.		·	(=,515)
Balance as of March 31, 2006 Unaudited	29,531,955	\$	9,572	\$	271,468	\$	9,428	\$	7,158	\$	297,626		44.00.0
Total comprehensive loss												\$	(4,826)

CONSOLIDATED STATEMENTS OF CASH FLOWS

U.S. dollars in thousands	Three	months	Year ended		
		March 31,	December 31,		
-	2007	2006	2006		
	Una	udited			
<u>Cash flows from operating activities</u>					
	\$ 2,568	\$ (3,513)	\$ 3,032		
Adjustments to reconcile net income (loss) to net cash used in operating activities:					
Equity in losses of affiliated companies	5,308	3,495	17,740		
Minority interest in losses of subsidiaries	(1,635)	(1,727)	(9,224)		
Loss (gain) from disposal of businesses and affiliated companies and changes in	(11.710)	(1.6)	(0.545)		
holdings in affiliated companies, net	(11,712)	(16)	(2,547)		
Loss (gain) from sale of investments in available - for - sale securities	(480)	150	(24,899)		
Gain from settlement of a subsidiary's loan	2.47	(2,708)	(2,708)		
Depreciation and amortization	247	270	1,192		
Equity in losses (gains) of partnerships	120	238	672		
Stock - based compensation and changes in liability in respect of call options	468	174	771		
Deferred taxes, net	1,460	(13)	(4,243)		
Changes in operating assets and liabilities	22	517	(455)		
Decrease (increase) in trade receivables	23	517	(457)		
Decrease (increase) in other receivables and prepaid expenses	196	68	(738)		
Decrease in trading securities, net	(1)	-	(2)		
Decrease (increase) in inventories and contracts-in-progress	106	67	(1,069)		
Increase (decrease) in trade payables	(834)	283	2,589		
Increase (decrease) in other payables and accrued expenses (mainly provision for	(6 (91)	102	7.105		
income taxes)	(6,681)	192	7,195		
Other	190	1,043	843		
Net cash used in operating activities	(10,657)	(1,480)	(11,853)		
Cash flows from investing activities	(5 000)		(10.205)		
Investment in affiliated companies	(5,999)	-	(18,395)		
Proceeds from sale of affiliated companies shares	413	-	992		
Change in cash and cash equivalents resulting from disposal of businesses and			(000)		
decrease in holdings in formerly consolidated subsidiaries (Schedule A)	- (1.40)	- (5.420)	(808)		
Investment in other companies	(140)	(6,439)	(25,153)		
Proceeds from sale of available for sale securities	4,069	21,353	82,332		
Investments in deposits	(6,256)	(20,379)	(40,183)		
Investment in available for sale securities	(12,841)	(23,166)	(35,377)		
Proceeds from deposits	8,550	53,650	72,878		
Purchase of property and equipment	(100)	(441)	(1,308)		
Proceeds from sale of property and equipment	(10.204)	15	19		
Net cash provided by investing activities	(12,304)	24,593	34,997		
Cash flows from financing activities	10	2.42			
Proceeds from options exercised	40	242	527		
Repayment of long-term loans	(2)	- (400)	(105)		
Decrease in short-term bank loan, net	176	(400)	208		
Receipt of short-term loans, convertible loans and long-term loans from minority	• • •				
shareholders of a subsidiary	268		2,660		
Net cash used in financing activities	482	(158)	3,290		
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	(22,479)	22,955	26,434		
CASH AND CASH EQUIVALENTS AT THE BEGINNING OF THE PERIOD	52,954	26,520	26,520		
CASH AND CASH EQUIVALENTS AT THE END OF THE PERIOD	30,475	\$ 49,475	\$ 52,954		

CONSOLIDATED STATEMENTS OF CASH FLOWS

U.S. dollars in thousands						
	Three ended I	Year ended December 31,				
	 2007		2006	2006		
	 Una	udited	<u> </u>			
Supplemental cash flow information:						
Cash paid for:						
Income taxes	\$ 7,642	\$	463	\$	794	
Interest	\$ 26	\$	17	\$	69	
Non cash transaction						
Proceeds from sale of an affiliate not yet received	\$ 413	\$		\$	-	

SCHEDULE A:

Change in cash and cash equivalents resulting from disposal of businesses and decrease in holdings in formerly consolidated subsidiaries

Assets and liabilities at date of sale:

Working capital (working capital deficiency), net (except cash			
and cash equivalents)	\$ -	\$ -	\$ 2,826
Property and equipment	-	-	709
Minority interest	-	-	(10,036)
Accrued severance pay, net	-	-	(215)
Long term loans	-	-	(1,401)
Proceeds from repayment of loans and sale of shares of former subsidiary	-	-	2,633
Other investments	-	-	(1,713)
Investment in affiliated Companies	<u> </u>		 6,389
Net decrease in cash and cash equivalents	\$ <u>-</u>		\$ (808)

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

NOTE 1:- GENERAL

The accompanying unaudited condensed interim consolidated financial statements have been prepared as of March 31, 2007, and for the three months then ended in accordance with accounting principles generally accepted in the United States (U.S. GAAP) relating to the preparation of financial statements for interim periods. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States but which are not required for interim reporting purposes, have been condensed or omitted. See Note 6 for the reconciliation from U.S. GAAP to accounting principles generally accepted in Israel ("Israeli GAAP").

These financial statements should be read in conjunction with the Company's annual financial statements for the year ended December 31, 2006 ("the Company annual financial statements") and accompanying notes.

The condensed interim consolidated financial statements reflect all adjustments which are, in the opinion of management, necessary to present fairly the financial position, results of operations and cash flows for the period presented.

Results for the three months ended March 31, 2007 are not necessarily indicative of the results that may be expected for the year ending December 31, 2007.

NOTE 2:- SIGNIFICANT ACCOUNTING POLICIES

- a. The significant accounting policies followed in the preparation of these financial statements are identical to those applied in preparation of the latest annual financial statements.
- b. The financial statements have been prepared in U.S. dollars, since the functional currency of the Company and its principal subsidiaries is the U.S. dollar.
- c. In July 2006, the FASB issued FASB Interpretation No. 48, "Accounting for Uncertainty in Income Taxes an interpretation of FASB Statement No. 109" ("FIN 48"). FIN 48 prescribes a comprehensive model for how a company should recognize, measure, present and disclose in its financial statements uncertain tax positions that the company has taken or expects to take on a tax return. FIN 48 states that a tax benefit from an uncertain position may be recognized only if it is "more likely than not" that the position is sustainable, based on its technical merits. The tax benefit of a qualifying position is the largest amount of tax benefit that is greater than fifty percent likely of being realized upon ultimate settlement with a taxing authority having full knowledge of all relevant information. The adoption of FIN 48 as of January 1, 2007 did not have any effect on the Company's retained earnings and financial position.
- d. In September 2006, the FASB issued SFAS No. 157, "Fair Value Measurements". SFAS 157 establishes a single authoritative definition of fair value, sets out a framework for measuring fair value, and requires additional disclosures about fair value measurements. SFAS 157 applies only to fair value measurements that are already required or permitted by other accounting standards. FASB 157 is effective for fiscal years beginning after November 15, 2007. The Company is currently reviewing this new standard to determine its effects, if any, on its results of operations.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

NOTE 2:- SIGNIFICANT ACCOUNTING POLICIES (Cont.)

e. In February 2007, the FASB issued SFAS No. 159, "The Fair Value Option for Financial Assets and Financial Liabilities" ("SFAS No. 159"), which permits companies to choose to measure certain financial instruments and other items at fair value that are not currently required to be measured at fair value. SFAS No. 159 is effective for fiscal years beginning after November 15, 2007. The Company will adopt SFAS No. 159 no later than January 1, 2008. The Company has not yet determined the effect of the adoption of SFAS No. 159 on its consolidated financial statements.

NOTE 3:- MAJOR TRANSACTIONS

a. **NetVision**

On January 25, 2007, NetVision Ltd. ("NetVision"), then held 36% by Elron and 36% by Discount Investment Corporation Ltd. ("DIC"), completed the merger with Barak I.T.C (1998) International Telecommunications Services Corp Ltd. ("Barak") and the merger with GlobCall Communications Ltd. ("Globcall"), following which NetVision purchased from Barak shareholders all of Barak's issued share capital in exchange for approximately 46.5% of NetVision's share capital immediately after the transaction ("Barak Merger"), and from DIC, all of GlobCall's issued share capital in exchange for approximately 7% of NetVision's share capital immediately after the Barak Merger and the transaction ("GlobCall Merger"). The above mentioned exchange ratios were based upon companies valuations, that were issued to the parties by independent appraisers, according to which NetVision's value was estimated to be between 533,000 NIS (approximately \$122,000) and 621,000 NIS (approximately \$142,000), Barak's value was estimated to be between 456,000 NIS (approximately \$105,000) and 529,000 NIS (approximately \$121,000), and GlobCall's value was estimated to be between 67,000 NIS (approximately \$15,000) and 90,000 NIS (approximately \$21,000). Barak is a subsidiary of Clal Industries and Investments Ltd. ("Clal"). Elron, Clal and DIC, are part of the IDB group and are considered entities under common control.

Following the transactions, Elron's, DIC's and Clal's holdings in NetVision is approximately 18%, 25% and 29%, respectively. The merger was recorded in NetVision's financial statements based on the fair market value of NetVision ordinary shares issued, according to the purchase method of accounting. As a result of the Barak merger and GlobCall merger, Elron recorded gain of approximately \$10,300 (\$9,100 net of tax). In addition, Elron recorded gain in the amount of approximately \$1,000 (\$800 net of tax) as a result of exercise of options and debentures in NetVision.

Elron continues to account for NetVision under the equity method of accounting as together with DIC and Clal, Elron has a significant influence over Netvision.

b. AqWise

On March 15, 2007, Elron completed the acquisition of approximately 34% of the outstanding ordinary shares of AqWise – Wise Water Solutions Ltd., an Israeli-based water technology company ("AqWise"), from Polar Investments Ltd. (TASE: PLR) and other existing shareholders in consideration for approximately \$3,400.

AqWise, headquartered in Israel with offices in Mexico, provides advanced biological wastewater treatment technologies. AqWise's patented AGAR® (Attached Growth Airlift Reactor) technology increases capacity and nutrient removal in wastewater treatment

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

NOTE 3:- MAJOR TRANSACTIONS (Cont.)

b. AqWise (Cont.)

plants, utilizing advanced bio film technology to be used in existing plants or in new plants with limited space.

The excess of the purchase price over the company's share in the assets acquired and liability assumed amounted to approximately \$3,400. The Company is evaluating the allocation of the purchase price to AqWise intangible assets.

Since the investment was in ordinary shares, the investment in AqWise is accounted for under the equity method of accounting under the provisions of APB 18.

c. Given Imaging

Subsequent to the balance sheet date, during May 2007 and through May 17, 2007 Elron purchased approximately 391,000 shares of Given Imaging Ltd. ("Given Imaging") on the open market for an aggregate purchase price of approximately \$9,900. As a result, our direct and indirect (through Elron's subsidiary RDC – Rafael Development Corporation ("RDC")) interest in Given Imaging increased from approximately 20.8% to approximately 22.1% of the outstanding ordinary shares of Given Imaging. DIC, a 49% shareholder of Elron, simultaneously purchased the same number of shares of Given Imaging for the same aggregate purchase price and now owns 15.3% of the outstanding shares of Given Imaging.

d. BPT

Subsequent to the balance sheet date, on April 19, 2007, Elron completed a new investment of \$1,125 in BPT (Bio-Pure Technology) Ltd. ("BPT"), in consideration for 1,723,709 series A preferred shares. The aggregate financing round of \$2,500 was led by Elron and Aurum Ventures M.K.I. In addition, as part of the transaction, Elron was issued with warrants to purchase an additional 430,927 preferred A shares at a price and upon conditions determined in the agreement. Following the investment, Elron holds approximately 19% of BPT on a fully diluted basis and on an as converted basis.

BPT, an Israeli based water technology company, provides advanced membrane-based separation solutions that address the unique needs of the water, wastewater treatment and chemical process industries and enable high-grade separation and re-use of water and valuable materials within the process.

BPT offers a cost-effective and environment-friendly process, employing its proprietary HMTTM (Hybrid Membrane Treatment) solution, based on NF (Nano-Filtration) membranes exhibiting high stability, selectivity and reliability. BPT's solutions address aggressive wastewater streams and water-intensive applications in a wide range of industries, such as pharmaceuticals, chemicals, agrochemicals, metals, food & beverage, drinking water, water re-use and desalination.

NOTE 4:- ASSET HELD FOR SALE

On April 25, 2007, a definitive agreement for the sale by our subsidiary, Elbit Ltd., of its real estate in Carmiel, Israel, was signed for approximately \$11,600. The agreement is subject to the right of the current tenant of the property, to notify Elbit within a period of thirty days, if it wishes to purchase the property on the same terms. The sale is expected to be completed during the second quarter of 2007. Upon completion of the sale, Elron expects to record a gain, after tax of approximately \$3,500, in the second quarter of 2007.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

NOTE 5:- CONTINGENT LIABILITIES

There were no material changes in the status of the Company's contingent liabilities as described in the Company's annual financial statements, the details of which are as follows:

- 1. During September 1999, the Company received a copy of a claim and a request to approve such claim as a class action on behalf of public shareholders of Elscint (formerly an affiliated company) against the Company and others. The allegation raised by the claimants related to the decision regarding the sale of Elscint's substantial assets. The class action claim is for an amount of approximately \$158,000, alternatively \$123,000. The claim alleges that the defendants, by their decisions regarding the sale of Elscint's assets, caused damage to Elscint and its minority shareholders. The plaintiff seeks a court order requiring Elscint, or the other defendants, to purchase from each of the members of the represented class all shares held by them at a price of \$27.46 per share. The claim has been stayed pursuant to an arrangement reached by the parties pending the outcome of the appeal in the claim described in paragraph 2 below. The arrangement provides that if the appeal as described in paragraph 2 below is accepted, then the proceedings to recognize the lawsuit as a class action will proceed. Otherwise, the application to recognize the claim as a class action suit will be dismissed. In light of the decision on the said appeal by the Supreme Court as described in paragraph 2 below, the Company has requested directions from the Court in regard to this action.
- 2. On November 2, 1999, the Company received a copy of a claim, and a request to approve such a claim, as a class action on behalf of some institutional investors and others and those who held shares in Elscint on September 6, 1999. The allegations raised against the Company and certain of its officers including former officers, among others, relate to the period prior to the sale of the Company's holdings in Elbit Medical Imaging ("EMI") (the parent company of Elscint and formerly an affiliated company). The claimants seek a court order pursuant to which EMI would be compelled to execute the alleged buy-out of Elscint's share at \$14 per share or other remedies. On August 16, 2000, the Haifa District court dismissed the application to recognize the claim as a class action. Some of the claimants applied for and were granted permission to appeal to the Supreme Court in Israel. On December 14, 2006, the Supreme Court referred the matter back to the Haifa District Court in order to decide whether the claim should be recognized as a class action. On April 11, 2007, the Haifa District court ordered that the plaintiffs submit a revised statement of claim as well as a revised motion to recognize the claim as a class action.

In addition, in February 2001, the claimants submitted a revised claim similar to the previous one but not as a class action

3. During September 2006, two claims were filed by a certain individual in the Haifa District Court against the same defendants (including the Company and certain officers and former officers of the Company) of the action described in paragraph 2 above and based substantially on the same facts of such action. The claims are for an undisclosed amount and also include a request to recognize the claims as class actions. The Court has determined that the defendants do not yet have to file statements of defense.

The Company denies all the allegations set forth as described in paragraphs 1, 2 and 3, and based on legal advice received, management is of the opinion that the Company has good defense arguments which, more likely than not, will cause dismissal of the above claims.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

NOTE 5:- CONTINGENT LIABILITIES (Cont.)

4. On September 20, 2006 Rafael Armaments Development Authority Ltd. ("Rafael") filed a claim with the Tel Aviv District Court against the company's 100% subsidiary, DEP Technology Holdings Ltd. ("DEP"), and RDC, 50.1% held by DEP and 49.9% held by Rafael, requesting the court to issue a declaratory order that Rafael is entitled to terminate the rights granted to RDC to commercialize technologies of Rafael for future development of products for use in non-military markets, pursuant to an agreement between DEP, RDC and Rafael. In December 2006, DEP and RDC filed statements of defense. The parties have agreed to refer to mediation proceedings.

Based on legal advice, the management is of the opinion that DEP and RDC have good defense arguments, which, more likely than not, will cause dismissal of the claim.

Three months ended

\$

(15,130)

(0.51)

(0.50)

(12,098)

(0.41)

(0.43)

NOTE 6:- RECONCILIATION TO ISRAELI GAAP

Net income (loss)

Basic net income (loss) per share

Diluted net income (loss) per share

The consolidated financial statements of the Company have been prepared in accordance with U.S. GAAP. Had the consolidated financial statements been prepared in accordance with Israeli GAAP, the effects on the financial statements would have been as follows:

a. Effect on the statement of operations:

			M	arch 31, 200	/	
	As	reported_	_	ljustments naudited	As	s per Israeli GAAP
Net income (loss) Basic net loss per share Diluted net loss per share	\$	3,462 0.09 0.09	\$	(16,011) (0.51) (0.51)	\$	(12,549) (0.42) (0.42)
		,		e months end arch 31, 2000		
	As	reported		ljustments naudited	As	s per Israeli GAAP
Net loss Basic net loss per share Diluted net loss per share	\$	(3,513) (0.12) (0.12)	\$	(4,682) (0.16) (0.16)	\$	(8,195) (0.28) (0.28)
				Year ended ember 31, 20	06	
	As	reported		ljustments Audited	As	s per Israeli GAAP

\$

3,032

0.10

0.07

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

NOTE 6:- RECONCILIATION TO ISRAELI GAAP (Cont.)

b. Effect on the balance sheet:

	March 31, 2007								
	A	As reported Adjustments				per Israeli GAAP			
			Uı	naudited					
Total assets	\$	321,875	\$	(61,714)	\$	260,161			
Total liabilities including minority interest		20,728		(230)		20,958			
Total equity		301,147		(61,944)		239,203			
			Dece	mber 31, 200	06				
					As	per Israeli			

		s reported		justments Audited	As	s per Israeli GAAP		
Total assets	\$	326,249	\$	(58,970)	\$	267,279		
Total liabilities including minority interest		28,745		(957)		29,702		
Total equity		297,504		(59,927)		237,577		

c. Material adjustments:

1. The abovementioned adjustments result primarily from the differences between U.S. GAAP and Israeli GAAP detailed in Note 26 to the Company's annual financial statements for 2006 and from the following:

a. NetVision

As described in Note 3a, under U.S GAAP the Barak Merger and GlobCall Merger were accounted in NetVision's financial statement at fair value according to the purchase method. Under Israeli GAAP, the Barak Merger and GlobCall Merger accounted as "as pooling" since these transactions are considered business combination between parties under common control. The difference between Elron's share in NetVision's shareholder's equity before and after the transactions was recorded by Elron as capital reserve, while under U.S GAAP it was recognized as a gain in the statement of operations.

2. Accounting Standard No. 29 - Adoption of International Financial Reporting Standards (IFRS):

In July 2006, the Israel Accounting Standards Board published Accounting Standard No. 29, "Adoption of International Financial Reporting Standards (IFRS)" ("the Standard"). Pursuant to the Standard, companies that are subject to the provisions of the Securities Law, 1968, and that are required to report according to the regulations

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

NOTE 6:- RECONCILIATION TO ISRAELI GAAP (Cont.)

c. Material adjustments: (Cont.)

published thereunder, will be required to prepare their financial statements in accordance with IFRS starting from the period commencing on January 1, 2008.

Since the financial statements are in accordance to US GAAP, the Company includes in its financial statements a note of reconciliation between US GAAP and Israeli GAAP. Commencing January 1, 2008 the Company will include reconciliation between US GAAP to IFRS in a note to its financial statements.

The Company is evaluating the effect of the new Standard on its financial statements.

ANNEX TO THE CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands

Details relating to major investments as of March 31, 2007:

	% of	Carrying value of the investment as of	Market value of the public traded investments as of:		
	ownership interest ⁽¹⁾	March 31, 2007 ⁽²⁾	March 31, 2007	May 17, 2007	
Consolidated Companies:					
Starling (3)	50%	(693)	-	-	
SELA (3)	39%	335	-	-	
Medingo (3)	50%	(128)	-	-	
Affiliated Companies (equity):					
Given Imaging Ltd. (Nasdaq: GIVN) (3)	21%	71,479	128,659	169,338	
NetVision Ltd. (TASE: NTSN)	18%	24,431	62,258	63,809	
ChipX AMT	29%	1,387	-	-	
Wavion, Inc.	35% 38%	3,831 46	-	-	
Galil Medical Ltd. (3)	20%	5,036	_	-	
3DV Systems Ltd. (3)	44%	2,965	-	_	
Notal Vision, Inc.	23%	(114)	_	_	
Aqwise	34%	3,422			
Available for sale:					
EVS (Nasdaq: EVSNF.OB)	9%	1,158	1,349	1,402	
MWise Inc.	7%	1,419	1,420	1,212	
Partnership:	7 0/	4.5			
Gemini Israel Fund L.P.	5%	16	-	-	
InnoMed Ventures L.P.	14%	3,193	-	-	
Cost: Jordan Valley Ltd.	27%	8,137	_	_	
Impliant Inc.	22%	8,340	_	_	
Teledata Ltd.	21%	16,000	-	-	
Nulens Ltd.	29%	4,360	-	_	
Brainsgate Ltd.	22%	6,949	-	-	
Enure Networks Ltd.	41%	2,215	-	-	
Pulsicom Israel Technologies Ltd.	18%	10	-	-	
Safend Ltd.	26%	3,700	-	-	
Neurosonix Ltd.	16%	2,850	-	-	
Atlantium Inc.	31%	10,006	-	-	

⁽¹⁾ On the basis of the outstanding share capital.

.

⁽²⁾ Includes loans and convertible notes.

Represents the carrying value and the ownership interest of the investment in Elron's books and Elron's share in the carrying value and ownership interest of the investment in RDC's books.